Skip to main content
Fig. 5 | Clinical Epigenetics

Fig. 5

From: Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

Fig. 5

Differential methylation associated with initial response does not provide information on response duration or progression. Heatmap showing the hierarchical clusterization of samples of response after more than 6 AZA cycles (n =9) and samples of progression (n =7) using the methylation status of CpG sites identified in Fig. 2

Back to article page
\